AstraZeneca: Pulmonary Disease, Chronic Obstructive trials

The registry lists 284 Pulmonary Disease, Chronic Obstructive studies with AstraZeneca as lead sponsor. 14 are open to participants now and 127 have results posted.

Early Phase 1 2Phase 1 42Phase 2 57Phase 3 77Phase 4 19No phase 90(a study in two phases counts in both)

Studies

Page 3 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Non-interventional Study of COPD Patients With Asthma Overlap Syndrome in Viet Nam and TaiwanCompletedNCT02878252
• Latin American Study of 24-hs Symptoms in Chronic Obstructive Pulmonary Disease (COPD) Patients; LASSYC StudyCompletedNCT02789540
• Observational Study of Obstructive Lung Disease (NOVELTY)CompletedNCT02760329
• DETECT-Register DocumEnTation and Evaluation of a COPD Combination TherapyCompletedNCT02552160
• ICS/LABA Adherence and COPD ExacerbationCompletedNCT02446041
• High Risk Populations Among COPD Patients in JapanCompletedNCT02413359
• Observational Multicenter Non-interventional Study on COPD Patients Treatment Strategies at the Time of Hospital Discharge and Within 12 Months of Follow-up on an Outpatient Primary Care BasementCompletedNCT02346292
• A Real-World Assessment of a COPD Disease Management Support Service (Me & My COPD)CompletedNCT02300090
• Non-interventional Study of Spirometry Use to Diagnose COPD (Chronic Obstructive Pulmonary Disease) and to Prescribe Treatment to COPD Patients in the Outpatient InstitutionsCompletedNCT02248909
• Randomized, Crossover Safety and Pharmacokinetics Study of PT010CompletedNCT02197975Phase 1
• Pharmacokinetics and Safety Study of PT010 in Healthy SubjectsCompletedNCT02189304Phase 1
• Evaluation of Clinical Effectiveness of Roflumilast in Routine Practice, in Chronic Obstructive Pulmonary Disease (COPD) Patients in GreeceCompletedNCT02187926
• Epidemiology of Chronic Bronchitis in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02128529
• Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPDCompletedNCT02109406Phase 2
• A Cross Sectional Disease/Condition Focused Observational Study on Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02100332
• Post Marketing Surveillance of Roflumilast in KoreaCompletedNCT02068456
• Clinical Practice of AECOPD Management in ChinaCompletedNCT02051166
• Patient Registry of Roflumilast In Real LifeCompletedNCT02015767
• Study to Investigate Safety, Tolerability and Effect of Multiple Dosing With AZD 4721 and/or With AZD 5069CompletedNCT01962935Phase 1
• Comparative Effectiveness of Symbicort vs. Advair Among COPD PatientsCompletedNCT01921127
• Comparative Effectiveness of Symbicort vs. Spiriva Among COPD PatientsCompletedNCT01917643
• A First Time in Man Study to Asses the Safety and Tolerability of AZD7624 in Healthy SubjectsCompletedNCT01754844Phase 1
• Perception of Symptom Variability in COPDCompletedNCT01753427
• Oxis 9mcg Turbuhaler Clinical Experience InvestigationCompletedNCT01749462
• Symbicort Turbuhaler 30/60 Special Clinical Experience Investigation for Long-term Use for Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT01713075
• Correlation Between Patient Perception and Findings on Clinical Examination in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT01703416
• Validation of Questionnaire and Assessment of Patient Satisfaction for Budesonide/Formoterol Fix Combination Dry Powder Inhalers (DPI) in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01646424
• CorRELation Between PatIent PErception and Findings on Clinical ExaminationCompletedNCT01627743
• AZD8683 Multiple Dose Study in Healthy Volunteers and Chronic Obstructive Pulmonary Disease (COPD) PatientsTerminatedNCT01584739Phase 1
• Multi-centre Study to Assess the Efficacy and Safety of AZD5423 in COPD Patients on a Background Therapy of FormoterolCompletedNCT01555099Phase 2
• A Single-dose Study to Investigate the Effects of 3 Different Doses of Inhaled AZD2115 in COPD PatientsCompletedNCT01498081Phase 2
• Prevalence Study and Regular Practice Among General Practitioners in Populations at Risk of Chronic Obstructive Pulmonary Disease (COPD) in Latin AmericaCompletedNCT01493544
• An Observational Study to Assess RSV-associated Illness in Adults With COPD and/or CHFCompletedNCT01455402
• Observational Study to Evaluate the Correctness of the Use of Inhaler Device in Patients With Asthma or Chronic ObstructCompletedNCT01426893
• Outcome Study Following Reimbursement Changes in the Use of Fixed Combination Inhalers in Patients With Asthma or Chronic Obstructive Pulmonary DiseaseCompletedNCT01369810
• Pharmacokinetic Study of Single and Repeated Dose of Roflumilast 500 µg , in Healthy Chinese SubjectsCompletedNCT01354782Phase 1
• PT005 MDI Dose Ranging Versus Foradil Aerolizer StudyCompletedNCT01349868Phase 2
• A Study of the Inflammatory Pathways Associated With Chronic Obstructive Pulmonary Disease ExacerbationsCompletedNCT01337661
• Cross-sectional Study to Investigate the Effects of Chronic Obstructive Pulmonary Disease on Daily Life ActivitiesCompletedNCT01325948
• Quality of Life in Daxas-treated Patients Older Than 18 Years With Severe COPDCompletedNCT01285180
• Quality of Life in Daxas-treated Patients Older Than 18 Years With Severe Chronic Obstructive Pulmonary Disease (COPD) (DACOTA)CompletedNCT01285167
• AZD2115 Single Ascending Dose StudyCompletedNCT01283984Phase 1
• A Study to Evaluate Biomarkers in Chronic Obstructive Pulmonary DiseaseTerminatedNCT01268072
• Impact of Morning Symptoms in Clinical Control of Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01266395
• Evaluation of an Oxygen Enhanced Magnetic Resonance Imaging Method on Patients With Chronic Obstructive Pulmonary Disease During 8 Weeks Treatment With Either Symbicort Turbuhaler or Oxis TurbuhalerCompletedNCT01257048Early Phase 1
• Predictive Questionnaires for Risk of Acute COPD (Chronic Obstructive Pulmonary Disease) ExacerbationsCompletedNCT01248507
• To Evaluate the Effect of AZD3199 on the Electrical Activity in the HeartCompletedNCT01222442Phase 1
• A Study for the Assessment of the Words Used by Patients and Physicians to Express the Symptoms of Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01219946
• Observational Study to Evaluate Health Status of Chronic Obstructive Pulmonary Disease (COPD) Patients in Response to Real-life Treatments in ThailandCompletedNCT01169727
• An Investigation of the Past 10 Yrs Health Care for Primary Care Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT01146392
• Study to Investigate Daily Symptom Variability, Symptom Effects on Morning Activities of Chronic Obstructive DiseaseCompletedNCT01110564
• This Study Will Investigate How Food and Age Effect the Way the Body Handles the AZD5069 Drug Given as a Oral DoseCompletedNCT01083238Phase 1
• A Study to Assess Safety, Tolerability and Pharmacokinetics of of AZD6553 in Healthy Volunteers and Patients With Chronic Obstructive Pulmonary Disease (COPD)TerminatedNCT01068184Phase 1
• Efficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active ControlWithdrawnNCT01043601Phase 2
• AZD9668 Relative BioavailabilityCompletedNCT01035411Phase 1
• AZD9668 Relative BioavailabilityCompletedNCT01034982Phase 1
• A Multiple Ascending Dose Study With AZD9164 Given for 13 Days in Healthy Male and Female Subjects and in Patients With Chronic Obstructive Pulmonary DiseaseTerminatedNCT01016951Phase 1
• A Descriptive Study to Explore Certain Characteristics of Patients at Risk for Chronic Obstructive Pulmonary Disease (COPD) in a Primary Care SettingCompletedNCT01013922
• Factors Determining Quality of Life Related to Respiratory Status According to Gender of Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT01007734
• Patient's Perception in Symptoms Related to Morning Activity Based on Chronic Obstructive Lung DiseaseCompletedNCT00894426
• Study to Evaluate the Safety and Efficacy of Inhaled PT005 in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00880490Phase 1/2
• Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00871182Phase 1/2
• Evaluation of Symbicort® Turbuhaler® (Budesonide/Formoterol) in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00837629
• The Use of a Forecasting System for Predicting Exacerbations of COPDCompletedNCT00788645Early Phase 1
• A Project Ensuring Quality and Cooperation in the Chronic Obstructive Pulmonary Disease (COPD) TreatmentCompletedNCT00772733
• European Non-interventional Study in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT00722267
• Symbicort in Chronic Obstruktive Pulmonary DiseaseCompletedNCT00612976
• Symbicort in Chronic Obstructive Pulmonary DiseaseCompletedNCT00611520
• SYMBICORT® in the Treatment of COPDCompletedNCT00564499
• Clinical Trial to Assess Rate of Onset of Bronchodilator Action in Severe Stable Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT00435760Phase 3
• Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. Ratio-Study. (BY217/M2-112)CompletedNCT00430729Phase 3
• Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPDCompletedNCT00421122Phase 3
• Airway Clearance StudyCompletedNCT00379028Phase 4
• Comparison Between Symbicort® and Prednisolone in COPDCompletedNCT00259779Phase 3
• Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-08)CompletedNCT00246935Phase 3
• Efficacy and Safety of Oral Roflumilast Taken Once Daily in Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (BY217/M2-119)CompletedNCT00242320Phase 3
• Efficacy and Safety of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-06)CompletedNCT00242294Phase 2/3
• Budesonide / Formoterol in Treatment of Exacerbations of COPDCompletedNCT00239278Phase 2
• Efficacy Study of the Effect of Budesonide on EmphysemaCompletedNCT00232674Phase 4
• A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPDCompletedNCT00206167Phase 3
• A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD PatientsCompletedNCT00206154Phase 3
• The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121)CompletedNCT00108823Phase 3
• OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)CompletedNCT00076089Phase 3
• Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)CompletedNCT00062582Phase 3